Drug Profile
641597
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 22 Aug 2005 Discontinued - Phase-I for Lipid metabolism disorders in USA (unspecified route)
- 10 Dec 2003 Phase-I clinical trials in Lipid metabolism disorders in USA (unspecified route)